The insider sales are mechanically tied to option exercises and are trivial relative to Teva's $40.5B market cap. No bearish signal. Monitor the upcoming H2 ramp implied by maintained non-GAAP EPS guidance of $1.91-$2.11 and the Fitch upgrade to BBB- for the real earnings story.
Drugs in focus
TEVA drug pipeline →AUSTEDO
● Neutral Named in this insider cluster- Impact
- Phase
- Approved
- Time to market
- Already on the market — first approved April 2017; Austedo XR approved February 2023
- Next catalyst
- None dated
What to watchAustedo is a mature, approved revenue driver for Teva, commercial execution and growth trajectory matter more than any single catalyst. Watch Teva's quarterly innovative brand revenue growth rate (43% LC YoY in H1 2026) and any label-expansion trial updates for downward drift potential, as the binary approval catalysts are years past.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $34.81entry
- T+1 · 3mo ago +1.58%α +0.97% · $35.36
- T+5 · 3mo ago +4.70%α +3.49% · $36.45
- T+20 · 3mo ago +5.16%α +4.56% · $36.61
- T+60 · 18d ago +20.91%α +22.58% · $42.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Teva insiders (Hughes and Jover) sold a combined $1.34M in open-market shares on August 3, 2026, at ~$34.88/share, following the exercise of stock options at $0 exercise price. The sales occurred just 8 days after Teva's Q2 2026 earnings miss (revenue -1% YoY, GAAP loss of -$0.49/share), and represent 0.003% of Teva's $40.5B market cap, a trivial amount. The cluster is entirely option-exercise-and-sell transactions, a routine pattern for tax/cash purposes, not a bearish signal.
Key Financial Metrics
Key Facts
- Two insiders sold $1.34M total (0.003% of $40.5B market cap)
- All sales were same-day option exercises at $0 exercise price, routine cash-out pattern
- Sales occurred 8 days after Q2 earnings miss (revenue $4.14B, -1% YoY; GAAP EPS -$0.49)
- No open-market purchases in the cluster, only derivative exercises followed by sales
Financial Impact
$1.34M in insider sales, representing 0.003% of market cap, immaterial
Risk Factors
- Q2 revenue decline of -1% YoY and GAAP loss of -$0.49/share
- $726M Emalex acquisition charge weighing on reported earnings
- Insider cluster may be misread as bearish by less sophisticated traders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TEVA-1786004921253 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $44.50 +3.10% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $44.50 0.00% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $44.50 0.00% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $44.50 +1.95% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $44.50 +2.91% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $44.50 +4.95% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $44.50 +4.95% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $44.50 +3.56% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $44.50 +3.56% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $44.50 +4.44% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers